Drew W. Pratt, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 2S235G
- Bethesda, MD 20892
Dr. Pratt’s laboratory seeks to use multi-omic (epi)genomic data, including DNA methylation profiling and DNA/RNA-seq, to refine the classification of cancer and to discover novel, clinically-relevant entities. This will ultimately lead to improved diagnostic precision and prognostication for patients.
Areas of Expertise
Current classification schemes of human tumors depend primarily on histologic appearance which, while of value, is subject to interpretive error and is not biologically based. As a consequence, many tumors elude precise classification, and a portion of cases are subject to interpretive error.
To address this problem, my primary research goal is to develop precise and reliable methods for the biologic classification of cancer using genomic/epigenomic data and bioinformatic techniques.
The adoption of molecular data into diagnostic neuropathology has resulted in an increase in clinically-relevant tumor types and their subsequent incorporation into the WHO Classification of Central Nervous System (CNS) Tumors. This paradigm shift reflects the significant biologic and, consequently, clinical heterogeneity of CNS tumors. However, current WHO nosology still retains traditional histologic classes and integrates them with available genetic information (e.g., mutations, copy number variants). There remains a need to refine and optimize current classification methods.
The goal of the lab is to improve cancer diagnostic precision using a critical diagnostic tool and emerging gold standard for pediatric and adult brain tumor diagnosis – DNA methylation array profiling. Successful implementation will lead to data-driven tumor classification schemes that are less prone to interpretive error.
To achieve this goal, the lab aims to: 1) adopt machine learning methodologies for reliable and accurate tumor class identification, 2) integrate multi-omic data (DNA methylation, RNA-seq, DNA-seq) for increased diagnostic resolution and precision, and 3) extend methylation- and multi-omics-based classification to systemic cancers.
A novel ATXN1-DUX4 fusion expands the spectrum of 'CIC-rearranged sarcoma' of the CNS to include non-CIC alterations
Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas
SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors
BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma
Drew W. Pratt, M.D.
Dr. Pratt received his medical degree from the University of Queensland in Brisbane, Australia. This was followed by residency training in anatomic pathology in the Laboratory of Pathology, National Cancer Institute and a fellowship in neuropathology at the University of Michigan in Ann Arbor. He then worked as Clinical Assistant Professor of Neuropathology at the University of Michigan with focused research interests in brain tumor epigenetics and bioinformatics. Dr. Pratt is board certified in both anatomic pathology and neuropathology. In 2021, he joined the Laboratory of Pathology as part of CCR's Physician-Scientist Early Investigator Program.
There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.
Learn more about CCR research advances, new discoveries and more on our news section.